Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Next Science Ltd ( (AU:NXS) ).
Next Science Limited announced that a derivative complaint filed by Michael Morello in Florida’s Duval County Court has been dismissed due to lack of standing. However, the litigation initiated by Next Science LLC against Mr. Morello and other former employees for breach of post-employment restraints is still ongoing, indicating continued legal proceedings that may impact the company’s operations and stakeholder interests.
More about Next Science Ltd
Next Science is a medical technology company based in Sydney, Australia, with a research and development center in Florida, USA. Founded in 2012, the company specializes in developing and commercializing its proprietary XBIO™ technology, which targets biofilm-based infections in human health. The XBIO™ technology is known for its non-toxic nature and effectiveness in eradicating both biofilm-based and free-floating bacteria, and Next Science holds full patent rights to this intellectual property.
YTD Price Performance: -28.57%
Average Trading Volume: 8,760
Technical Sentiment Signal: Buy
Current Market Cap: $17.14M
For detailed information about NXS stock, go to TipRanks’ Stock Analysis page.